Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | MPI | P34949 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30908496 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1880623 | 0.88 | ALDH1A1 (0.78) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL31345649 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4488260 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL32662668 | 0.79 | ALDH1A1 (0.66) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL29862350 | 0.79 | ALDH1A1 (0.66) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6509 | 0.79 | ALDH1A1 (0.66) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL378904 | 0.79 | ALDH1A1 (0.66) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22982789 | 0.79 | ALDH1A1 (0.66) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL15941760 | 0.79 | ALDH1A1 (0.66) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585247-A | Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain | 赛特温治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024074611-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023138599-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-116462662-A | Aromatic ring Nav1.8 inhibitor and application thereof | 成都康弘药业集团股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11685738-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | OCUTERRA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3259271-B1 | FLUORINATED DERIVATIVES OF 3-(2-OXO-3-(3-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-YL)PROPYL)IMIDAZOLIDIN-1-YL)PROPANOIC ACID AND USES THEREOF | SCIFLUOR LIFE SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3674301-A1 | FLUORINATED INTEGRIN ANTAGONISTS | SciFluor Life Sciences, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3266782-B1 | FLUORINATED INTEGRIN ANTAGONISTS | SCIFLUOR LIFE SCIENCES INC (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| EP-1372654-A2 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002081728-A2 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-0858444-A4 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-12-01 | — | — | EP | disclosed |
| EP-0858444-A1 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5750549-A | ANTIINFLAMMATORY AGENTS OR ANALGESICS | MERCK & CO., INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5710139-A | Heterocyclic compounds | ASTRA AB (SE) | 1998-01-20 | — | — | US | disclosed |
| WO-1997014671-A1 | CYCLOPENTYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| EP-0736032-A1 | HETEROCYCLIC COMPOUNDS | Astra Aktiebolag (SE) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017410-A1 | HETEROCYCLIC COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | HIPK3, HIPK1, HYPK | ALDH1A1 3983/4885CYP1A2 3658/4885CYP3A4 4511/4885 |
| US-11685738-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | FFAR3, FFAR2, FFAR1 | ALDH1A1 1949/4885CYP1A2 2338/4885CYP3A4 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.